Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAS3731
- Development stage
- Phase 1
- Lead developer
- Taiho Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TAS3731 is a small molecule drug developed by Taiho Pharmaceutical Co., Ltd. It is under clinical investigation primarily in healthy adults to evaluate safety and pharmacokinetics. The drug has shown neurite outgrowth promoting activity in preclinical studies, which suggests potential therapeutic effects on nerve function. In animal models of diabetic lower urinary tract dysfunction, TAS3731 improved voiding efficiency and suppressed residual urine volume without affecting blood glucose levels or causing toxicity. The exact mechanism of action remains unknown as of current data, but it appears to promote neuronal regeneration or repair.
- Other names
- TAS-3731TAS3731TAS 3731
Beyond the preview
Go deeper on TAS3731.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAS3731.